Anti-miR-135b in colon cancer treatment by Valeri, Nicola
   
 Università degli Studi di 
Ferrara
 
 
DOTTORATO DI RICERCA IN  
"Farmacologia ed Oncologia Molecolare" 
 
CICLO XXIV 
 
 
 
COORDINATORE Prof. Antonio Cuneo 
 
 
 
 
 
 
 
Anti-miR-135b in colon cancer treatment 
 
 
 
Settore Scientifico Disciplinare BIO/11 
 
 
 
 
 
 
 Dottorando                                                   Tutore 
 Dott. Valeri Nicola                                     Prof. Volinia Stefano 
 
_________________________               _____________________________ 
   
 
 
 
Anni 2009/2011 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
  
3 
 
Index 
 
Abstract Inglese        5 
 
Abstrac Italiano        7 
 
Introduction         9 
 
Results        11 
 
Discussion        25 
 
Materials and  Methods      31 
 
Reference List       39 
 
Figures        45 
 
 
 
 
 
 
 
 
 
 
  
4 
 
  
5 
 
 Abstract (English)  
 
Background: MicroRNAs (miRs) are small non coding RNAs involved in cell 
homeostasis. miRs are deregulated in colorectal cancer (CRC). Our study aimed 
at identifying miRs with a driver role in carcinogenesis altered by similar 
mechanisms in both human and mouse CRC. Goal of the study was to use CRC 
mouse models for the pre-clinical development of anti-miRs as therapeutic drugs. 
Methods: Azoximetane (AOM)/Dextran-Sulfate (DSS) treated mice or CDX2Cre-
APC f/wt mice were used to study inflammation-associated and sporadic APC-
related CRC. Human Inflammatory Bowel Disease associated (n=15), and 
sporadic (n=62) CRC with their matched normal tissues were collected according 
to Good Clinical Practice recommendation and subjected to RNA extraction using 
Trizol. miR and gene expression profiling was assessed by nCounter technology 
(Nanostring Seattle). Anti-miR-135b and scrambled probes for in vivo studies were 
synthesized by Girindus. Results: miRs profiling from AOM/DSS and CDX2Cre-
APC f/wt CRC revealed that miR-135b is one of the most up-regulated miRs in 
both models. In humans miR-135b over-expression was found in both IBD and 
sporadic CRC and was associated with reduced Progression Free Survival and 
Overall Survival in CRC patients. Molecular studies in Mouse Embryo Fibroblast 
and human CRC cell lines highlighted the role of two major pathways in the 
upstream activation of miR-135b: APC-β-Catenin and SRC-PI3K. MiR-135b up-
regulation resulted in reduced apoptosis and increased cell growth due to the 
down-regulation of TGFRB2, DAPK1, APC and FIH. Silencing of miR-135b in vivo 
reduced tumor multiplicity and tumor load in the AOM/DSS CRC model. Mice 
treated with anti-miR-135b showed well differentiated tumors and acinar pattern 
while tumors in the control groups showed low differentiation and adenomatous 
pattern. Conclusions: Our data suggest that miR-135b is a key molecule whose 
activation is downstream of oncogenes and oncosuppressor genes frequently 
altered in CRC. Our study defines specific pathways that converge on the  
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activation of the same microRNA. The “in vivo” silencing of miR-135 shows 
preclinical efficacy with low toxicity and represents the first in vivo study for the 
use of anti-miRs in CRC treatment 
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Abstract (Italiano) 
 
Introduzione: I MicroRNAs (miRs) sono dei piccoli RNA non codificanti coinvolti 
nell’omeostasi cellulare. L’espressione dei miR e’ deregolata nel tessuto tumorale 
dei pazienti affetti da cancro del colon retto. Il nostro studio e’ volto ad identificare 
microRNA implicati nella cancerogenesi del colon la cui espressione sia 
influenzata da meccanismi genetici simili nel topo e nell’uomo. Obiettivo dello 
studio e’ quello di usare modelli murini di cancro del colon per lo sviluppo pre-
clinico di terapie basate sull’impiego di anti-miR. Materiali e Metodi: Modelli 
murini di cancro del colon associati alla somministrazione di Azoximetane 
(AOM)/Dextran-Sulfate (DSS) o alla presenza di mutazioni di APC nel colon sono 
stati usati come modelli per il cancro del colon associato ad infiammazione o 
sporadico. Tessuti tumorali di cancro del colon associati a malattie ulcerose 
croniche o di tumori sporadici e i rispettvi tessuti normali adiacenti sono stati 
collezionati secondo le norme di Good Clinical Practice e sono stati sottoposti ad 
estrazione di RNA. Il profilo di espressione dei microRNA e’ stato valutato 
mediante nCounter technology (Nanostring Seattle). Oligonucleotidi Anti-miR-
135b o controllo per gli studi in vivo sono stati sintetizzati da Girindus Inc. 
Risultati: Il profilo di espressione dei microRNA nei due modelli murini 
sopraindicati ha identificato il miR-135b come uno dei microRNA maggiormente 
espressi in entrambi i modelli. In campioni di cancro umano il miR-135b e’ risultato 
iper-espresso sia nel cancro sporadico sia in quello associato a malattie 
infiammatorie croniche intestinali ed e’ risultato associato a ridotta sopravvivenza. 
Studi in vitro in fibroblasti embrionali di topo e linee cellulari umane di cancro del 
colon hanno dimostrato che il miR-135b e’ attivato da due sistemi di trasduzione 
del segnale frequentemente affetti da mutazioni nel tumore del colon: APC-β-
Catenina e SRC-PI3K. L’iper-espressione del miR-135b in linee cellulari umane 
era associata a ridotta apoptosi e aumento della crescita cellulare a causa 
dell’inibizione di numerosi geni onco-soppressori: TGFRB2, DAPK1, APC ed FIH.  
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L’inibizione del miR-135b in vivo e’ risultata in una riduzione del numero e del 
volume tumorale. I tumori dei topi trattati con anti-miR-135b risultavano ben 
differenziati e con pattern acinare mentre quelli dei topi del gruppo di controllo 
apparivano scarsamente differenziati e con pattern adenomatoso. Conclusioni: I 
nostri dati mostrano che il miR-135b e’ un importante onco-miR la cui attivazione 
e’ legata alla presenza di mutazioni frequentemente osservate nel cancro del 
colon. Il nostro studio identifica quali vie di trasduzione del segnale convergono 
nell’attivazione dello stesso microRNA. L’impiego di anti-miR-135b mostra buona 
efficacia e scarsa tossicità e rappresenta il primo studio in vivo per l’impiego di 
anti-miR come strategia terapeutica in un modello murino di cancro del colon. 
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 Introduction 
 
ColoRectal Cancer (CRC) arises trough the progressive accumulation of 
mutations in oncogenes and onco-suppressor genes1. Targeting driver oncogenes 
or using mutations as biomarkers for response to treatment represent the best 
option to tailor cancer treatment2.  Inhibitors of mutated oncogenes such as 
protein kinases have been developed and are currently used in clinical practice or 
under investigation in clinical trials3.  Targeting driver oncogenes in CRC is 
associated to increased Time To Progression  and Overall Survival (OS) in 
metastatic CRC patients3.  Even though promising this approach has two main 
pitfalls: 1) response to target therapies is limited in time because drug resistance 
arises as a result of the activation of collateral pathways4. 2) while specific 
inhibitors of driver onco-genes can be developed and exploited into drug 
development, targeting lost onco-supressor genes such as the Adenomatous 
Polyposis Coli (APC) remains challenging to translate into therapeutic weapons.  
microRNAs (miRs) are a class of small non-coding RNAs (19-25nt in length) 
involved in cell homeostasis and carcinogenesis5.  Several miRs are aberrantly 
expressed in colorectal cancer and their deregulation has been linked to CRC 
progression and clinical outcome6.   Different oncogenic pathways can merge on 
the same miR, as well as a single miR can control a general transcriptional 
program affecting dozens of target genes 5. Since miRs often act as downstream 
effectors of protein kinases or driver genes mutated in cancer7, targeting miR 
might represent a strategy to increase targeting specificity and overcome drug 
resistance. Furthermore the relative ease by which deregulated miRs can be 
detected in biological specimens from CRC patients increases the feasibility of this 
approach and its potential to be translated into a clinical setting8. Data on the 
efficacy of miR inhibition are available to date and prompt the use of anti-miR 
technology in CRC treatment in vivo 9.  
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Results 
 
Target selection 
In order to test which miRs are regulated in vivo by activating or inactivating 
mutations frequently occurring in CRC we ran a microRNA profiling on tumor and 
normal matched tissues from two different mice models of CRC. The CDX2P-NLS 
Cre;Apc+/loxP (CPC;Apc) model is characterized by the presence of a truncating  
mutation affecting one APC allele10.   The APC inactivation promotes the 
formation of an average of 5 to 8 tumors in the colon and rectum, 1 tumor in the 
cecum and  2-3 tumors in the distal small intestine in six months old mice10. The 
Azoximehtane (AOM)/Dextran Sulphate Sodium (DSS) model is due to the 
synergic effect of the pro-carcinogen AOM associated to the intermittent 
administration of the inflammatory stimuli exerted by the pro-inflammatory drug 
DSS11. This model is frequently associated to mutations in the PI3KCA, KRAS and 
SRC pathways. AOM/DSS mice develop an average of twenty polyps mainly in 
the distal colon after 11 weeks of treatment11,12. β-catenin mutations in exon 3 
have been described after AOM/DSS administration and depends often on the 
mouse strain used13. We sequenced exon 3 in the polyps of our AOM/DSS treated 
mice and no mutations were found. We used nCounter technology to run a 
genome-wide miR expression profiling in tumors and matched normal tissues from 
six mice for each model, CPC;APC and AOM/DSS. Both models have been 
developed using the C57BL6 strain allowing direct comparison between the two 
and avoiding biases due to different strains. Seventy-six miRs were aberrantly 
expressed in polyps from the CPC;APC model with P < 0.01, with 16 miRs 
increased and 17 decreased by greater than two fold. In the AOM/DSS model 94 
miRs were aberrantly expressed in polyps compared to normal tissues with P < 
0.01; among these, 15 miRs were increased and 9 decreased by greater than two 
fold (Figure 1). We focused on over-expressed miRs because we believe they 
have a stronger driver role in carcinogesis, and because silencing technologies 
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 proved to be more effective than re-expression approaches mediated by lentiviral 
delivery9. miR-135b was found as one of the most over-expressed miR in both 
models (Figure 1). Real Time-PCR validation confirmed the over-expression of 
miR-135b in both the CPC;APC(fold change cancer/normal: 8.6; p: 0.0061) and 
the AOM/DSS model (fold change cancer/normal: 7.5; p value 0.031).  In order to 
test whether inflammation itself was able to induce the over-expression of miR-
135b we included in the validation analysis colon mucosa from mice treated with 
short (7 days) or long (78 days) DSS alone. DSS alone did not affect miR-135b 
expression leading to speculate that the AOM pro-carcinogenetic stimulus is 
fundamental for miR-135b up-regulation. Further confirming this hypothesis, 
normal tissues from AOM/DSS mice showed increased miR-135b expression 
compared to normal tissues from untreated or CPC;APC mice (p <0.0001 for both 
comparisons) (Figure 2A).  
In situ hybridization (ISH) analysis revealed that miR-135b is strongly expressed in 
cytoplasm from dysplastic cells in both mouse models. Faint signal was also 
detected in inflammatory cells and normal epithelial cells from the intestinal 
cryptae (Figure 2B). 
 
MiR-135b is over-expressed in Human CRC 
MiR-135b has been consistently reported as up-regulated in cancer compared to 
normal tissue 14-18.  We validated these observations by testing miR-135b 
expression in both sporadic and inflammatory bowel disease (IBD)-associated 
CRCs. Sixty-two sporadic CRCs were analyzed for miR-135b expression by RT-
PCR. In line with data observed in mice19 and previous reports in humans14-18, 
miR-135b was up-regulated by an average 4 fold change in cancer compared to 
paired tissue (p<0.0001) (Figure 3A). When miR-135b was plotted against the 
tumor stage, miR expression correlated with tumor progression as it was 
increased in the sequence from Stage I to Metastatic Stage IV CRC (Figure 3B). 
The second analysis was performed in two independent sets of IBD-associated 
CRCs. In the first set of patients a paired analysis showed miR-135b up-regulation 
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in cancer compared to normal tissues (fold change 5.6; p: 0.0003) (Figure 3C). 
These findings were confirmed in the second set where miR-135b was also over-
expressed in dysplasia compared to normal tissues suggesting that miR-135b 
deregulation might be an early event in colon carcinogenesis (mean fold change 
7.15;  p:0.0057) (Figure 3D). ISH showed that miR-135b is expressed in 
cytoplasm of epithelial cells, while stromal cells show very weak signal. Normal 
colic epithelia do express miR-135b mainly in the cryptae suggesting a role for 
miR-135b in cell proliferation. Dysplasia and invasive CRCs show a very strong 
miR-135b signal compared to normal adjacent tissues confirming our previous RT-
PCR data (Figure 3E). 
 
MiR-135b is associated with poor prognosis in sporadic CRC 
In order to test if miR-135b can be associated to clinical outcome in CRC patients 
we plotted Kaplan–Meier survival curves for survival distributions and we 
compared them with the use of the Mantel–Cox log-rank test and the Wilcoxon 
test. Tumor stage, nodal status and miR-135b expression were identified as 
prognostic markers (Figure 4&5). The logarithmic ratio between miR-135b 
expression in cancer and normal tissue for each patient was used for the analysis. 
Patients were stratified in two groups according to miR-135b expression: high if 
miR-135b expression >2, and low if miR-135b expression  2. High miR-135b 
expression was associated to poor OS in the entire cohort of patients (p: 0.0044) 
and to poor Progression Free Survival (PFS) (Figure 5). A subgroup analysis in 
patients with stage II CRC identified a trend toward a worse prognosis for patients 
with high miR-135b. However, the difference was not statistically significant (p: 
0.055) likely due to the small sample size (Figure 5D). A multivariate analysis 
confirmed miR-135b as an independent prognostic factor associated to OS. 
 
MiR-135b over-expression is associated to mutations in specific CRC 
pathways 
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Data generated in mice suggested that miR-135b over-expression might be due to 
the involvement of several pathways. APC is the major player in the CPC;APC 
model10 while different pathways might be involved in the AOM/DSS model12. In 
order to confirm that miR-135b over-expression is due to APC loss we re-induced 
APC by transfecting a plasmid encoding the APC full coding sequence (CDS) in 
the SW480 human CRC cell line, which harbors a mutated APC isoform20. Re-
expression of Wild-Type (WT) APC caused a 6.8 fold change in APC expression 
(p:0.0338) and was able to cause a 48% reduction in miR-135b expression (p: 
0.0063) after 12h. On the contrary inhibition of APC by siRNA in two different 
normal colon epithelial cell lines, NCM4060 and NCM 356,21 resulted in a 2.2 
(p<0.001) and 4.1 (p: 0.011) fold change increase in miR-135b expression 
respectively (Figure 6A&B). In absence of Wnt signaling APC binds to β-catenin 
and induces its ubiquitination and subsequent proteolytic degradation. Activation 
of Wnt signaling by binding of Wnt ligands as well as by inactivating mutations in 
APC binding domains causes release and stabilization of β-catenin. Stabilized β-
catenin can then enter the nucleus and activate a complex transcriptional program 
through different effectors22. In order to test whether APC loss could result in miR-
135b over-expression through β-catenin stabilization we enforced β-catenin 
expression either by transfecting NCM 4060 cells with a plasmid encoding the β-
catenin protein or by stabilizing β-catenin with LiCl treatment. Both experiments 
resulted in increase in miR-135b expression [fold changes 3 (0.007) and 4.6 (p: 
0.02) for β-catenin plasmid transfection or LiCl treatment respectively] (Figure 
6C&D&E). To study which transcription factor may be responsible for miR-135b 
induction we used a series of siRNA against the major transcription factors 
involved in APC/ β-catenin axis activation. We selected two cell lines with high 
basal β-catenin activity: HCT-116 (β-catenin mutant23) or SW480 (APC mutant 
cells20). Silencing of the major transcription factors TCF4 and LEF1 resulted in 
miR-135b reduction in both cell models (Figure 6F&G). Interestingly, the use of 
siRNA against β-catenin did not alter the expression of miR-135b since in these 
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cells mutations in β-catenin or APC affect the β-catenin protein stability and not its 
transcription (Figure 6H).    
Other known transcription factors (RNX3.1, USF1 and c-myc) downstream of the 
β-catenin axis were also screened. While RNX3.1 and c-myc did not affect miR-
135b expression, USF1 silencing caused an increase in miR-135b expression 
suggesting that in physiological conditions USF1 might act in preventing miR-135b 
over-expression (Figure 6H).  
Our data taken together suggest that miR-135b can be activated by the APC/β-
catenin/TCF4-LEF1 pathway. 
To study the pathways involved in miR-135b over-expression in the AOM/DSS 
model we screened miR-135b expression in a series of Mouse Embryonic 
Fibroblast engineered to harbor mutations in specific key genes frequently 
mutated in CRC. The analysis showed that miR-135b is over-expressed in 
PI3KCA (both subunit alpha and delta mutants) and SRC mutated cells, while 
mutations in c-jun did not affect miR-135b expression (Figure 7A). To further study 
the role of PI3K in the modulation of miR-135b we used two human CRC isogenic 
cell lines (HCT-116 and DLD-1) in which either the PI3K mutant or wild-type allele 
has been disrupted24. In these cell lines the PIK3CA mutations have little effect on 
cancer phenotype under standard conditions, but cause reduced cellular 
dependence on growth factors affecting cell growth and apoptosis. RT-PCR 
analysis showed that miR-135b expression is increased by about 2 fold in PI3K 
mutant compared to WT cells in basal conditions (10%FBS). Serum starvation 
(0.5%FBS for 19 hours) forced the PI3K mutation phenotype, resulting in a further 
increase in miR-135b expression (3.8 and 4.3 in HCT-116 and DLD-1 
respectively) (Figure 8A&B). Serum starvation likely reduced the ability of WT cells 
to phosphorylate AKT, while mutant cells retained this ability in low growth factor 
conditions.  These experiments suggest that miR-135b is dependent upon PI3K 
activation. The observation that miR-135b increased at a similar extent in either 
cell lines suggested that the activation of miR-135b is independent on whether the 
mutation affects the helical or the kinase domain. Further confirming these 
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observations we treated engineered HCT-116 cells with the PI3KCA inhibitor 
LY294002 after starvation and we observed that LY294002 had no effect on WT 
cells but reduced the expression of miR-135b by 55% in mutant cells (Figure 
9A&B). We have proved so far that miR-135b expression is controlled by PI3K. 
The transcription factors Foxo1 and Foxo3A have been previously shown to 
promote the PI3K cancer associated phenotype in these engineered cell lines24. In 
order to investigate whether miR-135b is under the control of the Foxo 
transcription factors family we silenced Foxo1 and Foxo3A by siRNA in HCT-116 
PI3K WT cells and observed an increase in miR-135b of two fold. Of note, 
silencing Foxo 1 and 3a in WT cells increased miR-135b to levels similar to those 
observed in PI3K mutant cells (Figure 9C&D). In conclusion, PI3K mutations seem 
to induce miR-135b by phosphorylating and inactivating Foxo1 and Foxo3A.   
SRC is a member of a non membrane receptor tyrosine kinase family that act on 
cell proliferation, invasion and metastasis2
2 55 . SRC can induce activation of several 
pathways such as MAPK/RAS/RAF, PI3K/AKT and STAT3 among others. miR-
135b was found over-expressed in SRC mutated MEFs compared to WT cells 
(Figure 7A). Dasatinb26, a specific SRC inhibitor, was able to reduce the 
expression of miR-135b in both SRC mutated MEFs and in SW620 CRC cells 
(Figure 10A&B&C). In the latter case the expression of miR-135b was reduced to 
levels observed in SW480 CRC cells. SW480 are the SW620 parental cells and 
show reduced SRC27 activity compared to their metastatic derivative. Since SRC 
can activate a plethora of target downstream effectors we focused only on those 
previously analyzed in our MEF screening: PI3K and MAPK. Our data suggested 
that MAPK pathway is not responsible for miR-135b over-expression since 
mutations in c-jun which represents one of the main effectors of MAPK28 showed 
no increase in miR-135b expression. Further confirming these data we used 
specific inhibitors of PI3K or MAPK pathway. In line with our previous findings 
LY294002 was able to reduce the expression of miR-135b by 40% (p:0.029) in 
SRC mutant MEFs while MEK1-229 inhibitor did not affect miR-135b expression 
(Figure 10D&E). These observations allowed us to speculate that, at least in part, 
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SRC induces miR-135b over-expression trough the PI3K/AKT/Foxo pathway.  
SRC affect several pathways simultaneously, thus we cannot rule out the 
possibility that other SRC down-stream effectors might be responsible for miR-
135b over-expression. This hypothesis is supported by the observation that PI3K 
inhibition only in part reduces miR-135b expression and cells harboring mutations 
in both APC/ β-catenin and PI3K pathways still show statistically significant 
differences in miR-135b expression. 
MiR-135b is located on the negative strand of 1q32.1 (GRCh37 1: 205417430-
205417526 [-]) and overlaps with two isoforms of the LEM domain-containing 1 
(LEMD1) gene (LEMD1-002 protein coding and LEMD1-005 non protein coding) 
(Figure 11A). LEMD1 is a cancer testis associated gene found in prostate cancer 
30 and Anaplastic Cell Lymphoma31.  Gene-expression analysis suggests that only 
a (657 nt) LEMD1 isoform is expressed in CRC32. In order to test if miR-135b is 
under the control of the LEMD1 promoter or under the control of an independent 
promoter we tested in parallel the expression of LEMD1 and miR-135b in a series 
of experiments in which we manipulated transcription factors involved in miR-135b 
expression. RT-PCR using LEMD1 primers that cover all the different spliced 
LEMD1 isoforms revealed no correlation between miR-135b and LEMD1 
modulation suggesting that miR-135b promoter might be independent from 
LEMD1 promoter (Figure 11B).  
 
MiR-135b affects apoptosis and cell growth 
Our data show that miR-135b is associated with APC and PI3K mutations trough 
conserved mechanisms in mouse and humans. MiR-135b is associated to tumor 
stage and progression. In order to test if miR-135b deregulation is a consequence 
of cancer progression or actually drives colon carcinogenesis we tested the effect 
of miR-135b manipulation on apoptosis and cell growth.  
APC loss is linked to reduced apoptosis in CRC cells. Indeed, re-expression of 
APC is able to increase apoptosis and induce cell cycle arrest in SW480 cells33,34. 
To test the contribution of miR-135b on APC mediated apoptosis, we co-
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transfected SW480 cells with a plasmid encoding the full APC CDS (APC-EGFP) 
or an empty vector (Empty-EGFP) in combinations with LNA-anti-miR-135b, pre-
miR-135b or relative scrambled oligos. In line with previous evidence, APC re-
expression was able to induce apoptosis 18 hours after transfection in APC-
Scrambled-LNA transfected cells (90% increase compared to Empty-EGFP-
scrambled-miR transfected cells). Similarly, the inhibition of miR-135b alone 
induced apoptosis in SW480 cells (40% increase compared to Empty-EGFP-
scrambled-miR transfected cells). The co-transfection of miR-135b and APC-
EGFP was able to rescue the effect on apoptosis due to the re-induction of miR-
135b (Figure 12). These data taken as a whole suggest that APC induced 
apoptosis is due in part by down-regulation of miR-135b. It is worth to mention that 
APC is a putative target of miR-135b but in our experiments the APC-EGFP vector 
contains only the APC CDS and not the APC 3’UTR where the miR-135b seed 
region is harbored. These observations suggest that the rescue effect exerted by 
miR-135b on APC induced apoptosis is not due to a direct interaction miR-135b-
APC; it is caused instead by the effect that miR-135b exerts on other targets 
downstream of APC.  
To test the effects of miR-135b on anchorage dependent and independent cell 
growth we used the HCT-116 PI3K mutant and WT cells24. In this isogenic cell 
lines the presence of activating mutations in PI3K leads to increased proliferation 
under stress condition (i.e. growth factor deprivation and/or serum starvation). To 
test whether miR-135b could affect PI3K driven cell growth we over-expressed 
miR-135b in PI3K WT cells and we silenced miR-135b in PI3K mutant cells 
(Figure 13). PI3K WT cell over-expressing miR-135b showed increased 
proliferation after 48 hours and the difference was still statistically significant at 5 
days. Similarly, PI3K mutant cells transfected with anti-miR-135b showed reduced 
proliferation compared to the LNA-control cells (Figure 14A). The presence of 
PI3K mutations affected also the growth in soft agar. Silencing of miR-135b 
reduced the number of colonies in the PI3K mutant cells, while miR-135b over-
expression resulted in increase colony formation. As previously shown, the total 
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number of colonies is not altered but only the number of colonies with a diameter 
grater than 2 mm24 (Figure 14B&C). 
Our findings confirmed that miR-135b has a driver role in colon carcinogenesis 
being responsible at least in part for the APC effect on apoptosis and the PI3K 
effect on cell growth. 
 
MiR-135b targeting in vivo affect tumor number and tumor size 
In order to test if miR-135b silencing can affect apoptosis and cell proliferation in 
vivo we treated AOM/DSS mice with Anti-MiR-135b oligonucleotides (miR-135b-
AMO) or anti-scrambled-oligonucleotides (Scrambled-AMO). 2-MOE 3’Colesterol 
conjugated anti-miR-135b antisense oligodeoxyribonucleotide and scrambled 
probes were designed to target miR-135b or a random non-targeting sequence. 
We initially screened the 135b-AMO silencing efficacy in vitro in two different CRC 
cell lines that express high basal levels of miR-135b (HCT-116 and SW480). MiR-
135b-AMO caused a 57% down-regulation in miR-135b expression in vitro after 
48h, and a similar effect was still evident after 72 hours (Figure 15A). We checked 
for potential miR-135b-AMO off-target effects by looking at expression of other 
microRNAs (miR-21, miR-155, miR-221 and miR-16). None of these miRs was 
affected by miR-135b-AMO (Figure 15B). Bio-availability of the miR-135b-AMO 
was checked in vivo by injecting the oligonucleotide i.p. at 75mg/kg in 8 weeks old 
C57BL6 mice. Mice were euthanized 48 and 72 hours after miR-135b-AMO 
injection. Mice intestines and livers were collected. In order to detect miR-135b-
AMO in the mouse tissues we designed an LNA oligonucleotide specific to 
recognize the AMO probe. In Situ Hybridization for Anti-Anti-miR-135b revealed a 
strong signal in colon tissues suggesting that the miR-135b-AMO probe was 
retained in the mice intestine. Interestingly, the signal was mainly located in the 
epithelial cells, while little or no signal was observed in stromal cells suggesting a 
selective uptake of the AMO by the epithelial compartment (Figure 15C).  
In order to test miR-135b-AMO efficacy we induced colon polyps in 32 C57BL6 
mice using the AOM/DSS protocol (Figure 16). Eight mice received miR-135b-
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AMO i.p. twice per week at a dosage of 75mg/kg (miR-135b-AMO group), eight 
mice received Scrambled-AMO with the same schedule (Scrambled-AMO group), 
while eight mice received no AMO for the entire duration of the protocol (control 
group). 
None of the mice showed signs of toxicity related to AMO treatment or had to be 
euthanized before the end of the study because of toxicity. General side effects 
associated to the DSS administration (weight loss, diarrhoea and rectal 
bleeding11) were observed in both arms with no difference in term of severity or 
number of mice affected.   
After 12 weeks mice were euthanized and different organs were collected for 
further analyses. Mice colons were inspected during the necroscopy: tumors were 
counted and tumor size was measured using a calliper. The median number of 
tumors (tumor multiplicity) was 14.5. in the Scrambled-AMO group and 9.5 in the 
MiR-135b-AMO group (p: 0.016). The sum of tumor diameters (tumor load11) in 
the miR-135b-AMO group was reduced in comparison with the Scrambled-AMO 
group (13.9 Vs 27.5 p<0.0001). The difference in number of tumors with diameter 
grater than 2 mm was also statistically significant (3.5 in Scrambled-AMO Vs 1 in 
miR-135b-AMO p<0.001). The Average size of tumors was 2 mm and 1.5 mm in 
the Scrambled-AMO and miR-135b-AMO group respectively (p<0.001). The 
distribution of tumors by size also varied in the two group with increased number 
of tumors less than 1 mm in diameter in the miR-135b-AMO group. No differences 
were observed between the Scrambled-AMO and the control group (Figure 
17&18A). These observations suggested that miR-135b can affect both tumor size 
and tumor number. Microscopic analysis of the tumors in the two groups revealed 
a different pattern of differentiation and architecture between the miR-135b-AMO 
and the scrambled-AMO group. MiR-135b-AMO tumors were well differentiated 
and presented an acinar pattern while tumors in the Scrambled AMO group as 
well as those in the control group showed low differentiation and adenomatous 
pattern (Figure 18B). 
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Real-Time PCR and ISH for miR-135b in the miR135b-AMO mice revealed that 
miR-135b was expressed to similar level in cancer and matched normal tissues. In 
Scrambled-AMO and control mice miR-135b was over-expressed in cancers 
compared to controls and the fold change between malignant and normal tissues 
were similar to those observed in the initial screening (Figure 19A&B).  
Microscopic analysis suggested that miR-135b silencing might effect both 
proliferation and differentiation. We had previously shown miR-135b might control 
cell growth and apoptosis. In order to test the miR-135b-AMO effect on 
proliferation we performed immunohistochemistry for Ki-67 in colon tissues from 
miR135b-AMO, scrambled-AMO and control mice. Ki-67 scored positive in 60% of 
the tumors in the scrambled group while anti-miR-135b tumors had a reduced 
expression in the neoplastic cells. Ki67 signal was homogeneously distributed in 
the entire section from Scrambled-AMO mice and identified high proliferation 
index in different sections from different areas of the intestine (60% in Scrambled 
Vs 35% in the miR-135b-AMO). On the contrary Ki-67 showed a scattered pattern 
with differences in intensity and distribution in different areas of the intestine often 
reflecting different miR-135b expression (Figure 20A). 
To study apoptosis we performed an Immunofluorescence based Tunel Assay. 
The percentage of apoptotic cells and the intensity of the signal were reduced in 
the anti-miR-135b tumors in comparison to the Scrambled-AMO tumors. Similarly 
to Ki-67 staining, the signal was not homogeneous in the same colon section or in 
different section leading us to hypothesize that these difference might reflect 
different uptake of the 135b-AMO in different areas of the mice intestine (Figure 
20B).     
Liver, spleen kidneys and lungs from different mice from the three treatment 
groups were analyzed to detect changes in morphology or miR-135b expression: 
no significant differences were observed found (Figure 21).  
Taken together our in vivo data suggest that anti-miR-135b has an effect on both 
tumor load and tumor multiplicity. Since differentiation results from the balance 
between proliferation and apoptosis we suggest that differences in architecture 
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and differentiation might be due to the miR-135b effect on both cell growth and 
cell death. 
 
 
miR-135b targets onco-suppressor genes involved in apoptosis, 
proliferation and invasion. 
In order to find potential target genes affected by miR-135b over-expression we 
performed a gene expression in normal epithelial colon cells over-expressing miR-
135b 
NCM 4060 cells represents a good model for miR-135 over-expression since it is 
a normal colon epithelial cell line, is not affected by any mutation and shows very 
low basal expression of miR-135b (Figure 22).  Matched analysis of a cancer 
associated gene panel and target prediction algorithms showed that several genes 
were potentially controlled by miR-135b; amongst them Factor Inhibiting HIF1a 
(FIH), Transforming Growth Factor β Receptor 2 (TGFR2), and Death-associated 
protein kinase 1 (DAPK1) (Figure 23A).  FIH is an asparagine hydroxylase that 
catalyzes the hydroxylation of a single conserved asparaginyl residue in the C-
terminal transactivation domain of HIF-α, preventing HIF1α to exert its 
transcriptional activation in normoxia. TGFβR2 is a receptor transmembrane 
kinase involved in apoptosis and proliferation frequently down-regulated in CRC. 
DAPK1 is a calmodulin dependent serine-threonine kinase involved in 
programmed cell death. 
Data from the array analysis were confirmed by RT-PCR in the same cell line and 
in a second normal epithelial cell line (NCM 356) after miR-135b over-expression 
(Figure 23&24). Using prediction algorithms we identified predicted binding sites 
for miR-135b in each of these gens. Luciferase experiments were performed in 
order to validate the prediction models. The 3’UTR of the gene of interest was 
sub-cloned downstream of the luciferase CDS; NCM 4060 cells were co-
transfected with the luciferase construct, the pre-miR-135b or the pre-miR control 
and PD-TK as internal control. Over-expression of miR-135b was able to induce a 
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significant reduction in the expression of luciferase in the analyzed genes. 
Deletion of the miR-135b predicted seed region resulted in restoration of the 
luciferase activity confirming the specificity of the miR-135b-target interaction. 
Luciferase for APC was also performed in parallel and used as positive control 
(Figure 25).Western blotting analysis confirmed that over-expression of miR-135b 
induces reduction in protein expression of FIH, TGFR2, and DAPK1 (Figure 26). 
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Discussion 
 
Our findings identify miR-135b de-regulation as a consequence of mutations 
frequently occurring in CRC. MiR-135b over-expression is associated to increased 
proliferation and reduced apoptosis in vitro and recapitulates, at least in part, the 
phenotype associated to APC loss or PI3K activation. miR-135b silencing results 
in a reduction in the number and size of CRC in vivo representing a potential novel 
weapon strategy in CRC treatment. 
MiR-135b expression data in mice tumors and in human CRC suggest that miR-
135b up-regulation is an early event in tumor progression. Indeed miR-135b is 
increased in mouse polyps and in the sequence normal-dysplasia-cancer in the 
IBD associated CRC. Confirming this hypothesis we found that the two major 
driver events in miR-135b over-expression are represented by APC truncating 
mutations and PI3K activating mutations. Both mutations occur very early in the 
adenoma-carcinoma sequence1,35.  
Our observations are in line with a recent report that identifies miR-135b as one of 
the most up-regulated miR in the Inflammation-associated cancers and in the 
APCmin/+ mice19. The analogies in miR-135b expression between our model 
(CPC;Apc) and the APCmin/+ mice suggest that miR-135b deregulation is 
independent of the specific APC mutation or site of inactivation (small versus large 
bowel). In the same report19, in analogy with our findings, miR-135b was not 
induced by inflammation alone suggesting that the synergic effect of pro-
carcinogen and inflammation is crucial for the development of mutations leading to 
miR-135b deregulation.     
The observation that miR-135b is progressively increased in more advanced CRC 
stages and is associated to poor prognosis suggests that other genetic 
aberrations might be in control of miR-135b expression. Our data suggest that 
SRC, a tyrosine-protein kinase frequently mutated or over-expressed in advanced 
and metastatic CRC might be responsible for miR-135b deregulation in advanced  
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stages25. According to our model SRC exerts its activity on miR-135 expression 
trough different mechanisms. PI3K is one of the SRC down-stream effectors and 
seems to be involved in SRC dependent miR-135b over-expression. However 
PI3K inhibition exerts only a partial effect in reducing miR-135b expression in 
SRC-MEF compared to WT-MEF suggesting that other mechanisms are in control 
of SRC mediated miR-135b expression. These mechanisms are probably related 
to pathways other than MAPK. Indeed, either over-expression of AP-1 in MEFs or 
MAPK inhibition in SRC modified MEFs seem no to be involved in controlling miR-
135b. At the same time PI3K inhibition in SRC over-expressing cells causes on a 
partial decrease in miR-135b expression. We speculate that other effectors such 
as STAT3 might be involved in miR-135b control. This hypothesis is supported by 
a recent report that linked miR-135b over-expression to NPM-ALK trough STAT3 
in Anaplastic Large Cell Lymphoma31. The same report shows that miR-135b 
target Foxo1; this observation lead to consider miR-135b at the center of a 
feedback loop in which aberrant activation of PI3K/AKT/Foxo leads to miR-135b 
over-expression which in turn further down -regulates Foxo1.   
We identify TCF4/LEF1 as the main transcription factor complex involved the 
APC/β-catenin control of miR-135b regulation. However other transcription factors 
might be involved in the fine tuning of miR-135b regulation. Indeed USF-1 seems 
to play as a negative regulator of mir-135b expression. The presence of multiple 
transcription factors regulating miR-135b might explain why DLD-1 cells which 
harbor mutations in both APC and PI3K and similar SRC activity compared to 
HCT-116 show a significant difference in term of miR-135b basal expression. The 
use of animal models and MEFs characterized by different mutational background 
allows the dissection of specific pathways involved in microRNA control. Two 
important questions arise when applying these models to human CRC that display 
high heterogeneity. The first question relates on how different pathways crosstalk 
and /or act synergistically in promoting miR-135b expression. The second 
question is to understand whether the progressive and synchronous miR-135b up-
regulation can lead to an accelerated cancer phenotype.  The analysis of miR-
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135b expression in human CRC cell lines suggests that miR-135b expression 
follows the accumulation in APC/PI3K and SRC mutations. RKO cells lack 
mutations in APC/β-catenin and show low basal SRC activity but have mutations 
in PI3K,36-38 and are characterized by a moderate-low miR-135b expression 
(Figure 22). HCT-116 cells show β-catenin activating mutation23, PI3K 
mutations24,38 and moderate SRC36 activity and present with an increased miR-
135b expression compared to normal epithelium or RKO cells. Finally, parental 
cells SW480 and metastatic derivative SW620 show the same mutations for APC 
and PI3K but different SRC38 activity and show a different pattern in miR-135b 
expression. The use of CRC cell lines alone allows only observational analysis 
while the use of consecutive rounds of gene targeting to knock-in oncogenes and 
knock-out multiple tumor suppressor genes may be used to generate isogenic 
combinatorial models that better resemble tumor plasticity. Crosstalk among 
different pathways is frequently observed in colon carcinogenesis; however, it 
seems unlikely that this might affect miR-135b expression. Since GSK3 is a key 
component of both APC/β-catenin and PI3K/AKT pathways, it is widely assumed 
that active PI3K signaling feeds positively into the Wnt pathway by protein kinase 
B (PKB)-mediated inhibition of GSK3. However, recent reports suggest that 
different pools of GSK3 kinases exist in cells, participating separately in the 
PI3K/PKB pathway or the Wnt/β-catenin pathway39. This molecular arrangement 
allows Wnt and PI3K inputs to have independent effects on the biological outputs 
of the cells that receive these signals. These observations suggest that miR-135b 
can be activated separately by the two axis but no feedback loops between the 
two systems should be involved.  
Our data, in line with previously reported data suggest that APC is controlled by 
miR-135b18. Our array analysis also suggests that miR-135b can increase the 
transcription of β-catenin. These two observations suggest that miR-135b might 
be involved in a feed forward control loop. However, while miR-135b activation by 
the APC/β-catenin has an effect on cancer phenotype and might be of clinical 
relevance, the effect of miR-135b on APC/β-catenin is not completely clear. In 
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sporadic CRC, 80% of the tumors show somatic mutations in APC, thus in the 
remaining 20% miR-135b might contribute in controlling APC35. In IBD associated 
CRC, APC mutations are infrequent40 and miR-135b which is highly expressed 
might have an effect on APC expression. However we must point out that while 
the effect of miR-135b on APC/β-catenin has been showed in vitro   the effect of 
miR-135b on APC expression in vivo (human CRC) is not clear. IBD associated 
CRC show high miR-135b and often low APC signal but no nuclear β-catenin 
staining is observed in the same samples40. Agami and colleagues compared the 
expression levels of miR-135b in tumors with or without aberrations in the APC 
gene and found no association between APC mutations and miR expression18. 
We believe that the presence of multiple genomic aberrations simultaneously 
responsible for miR-135b over-expression might be able to explain why no 
correlation between miR-135b expression and mutations in APC genes have been 
previously reported.  
miR-135b is located within the exon 1 of LEMD1. According to our experiments 
miR-135b and LEMD1 are associated to two different promoters since 
manipulation of APC or PI3K pathway can affect miR-135b expression leaving 
LEMD1 expression unaffected. 
Matsuyama at al31 previously reported that STAT3 can affect simultaneously miR-
135b and LEMD1 expression. This discrepancy might be explained by the 
observation that miR function and regulation varies depending on tissue and cell 
specificity5. Furthermore five or more different LEMD1 splicing variants have been 
described32, their expression varies a lot among different tissues and only one 
isoform seems to be expressed in CRC. The same observation might explain why 
PI3K seems not to be effective on miR-135b expression in Lymphoma but exerts a 
strong effect in CRC.   
MiR-135b exerts its effect on proliferation, apoptosis and invasion by controlling 
different targets: TGFRβ2, DAPK1 and HIF1AN. TGFRB2 receptor levels are 
frequently down-regulated in both sporadic and IBD associated CRC35. 
Interestingly alteration in the expression of TGFRβ2 can affect the induction of 
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apoptosis by TGF beta by modulating SMAD dependent and independent 
pathways41,42. Similarly DAPK1 is frequently found down-regulated in both AOM 
CRC model and human CRC43,44. Interestingly, while DAPK1 is frequently silenced 
by methylation in hematological and some solid malignancies, DAPK1 promoter 
methylation is infrequent in CRC43,44.  
MicroRNA based therapeutics represent a promising tool for targeted cancer 
treatment since the same microRNA can regulate several survival-signaling 
pathways9. This observation summarizes promises and potential pitfalls of miR 
based therapeutics. If a single miR can affect several oncogenic pathways, it 
might also affect several cell homeostasis pathways crucial for cell physiology. 
MiR-21 for example can be considered a major onco-miR but is also central in 
cardiovascular physiology9. Thus selection of the right target is a central issue to 
avoid massive off-target effects. Contrary to miR-21, miR-135b basal expression 
is very low in normal epithelium as well as other organs suggesting that silencing 
miR-135b in normal intestine might have little or no effect on intestinal physiology. 
Anti-miR technology shows more potential than miR replacement technology. 
Even though miRs are smaller and less antigenic than protein-coding genes, miR 
delivery still represent an issue since viral-based delivery mechanisms are hardly 
translatable into clinical practice9. On the contrary miR silencing by specific 
antagomiRs or small sponges that soak-up a broader spectrum of miRNAs, can 
be efficiently achieved with an in vivo effect that can be sustained from few days 
up to 3 weeks9. Systemically delivered antagomirs have been successfully 
employed in liver and metastatic cancer models and are currently undergoing 
clinical trial testing45,46. Beside bioavailability and toxicities related to miR 
conjugation that might be in some way common to anti-miR and miR replacement 
therapies, anti-miR technology offers a major advantage over miR replacement: 
miRNA over-expression could cause saturation of the miRNA machinery and non-
specific effects. For example, Exportin 5 and Argonaute 2, two key miRNA 
processing components, are down-regulated when miRNA levels are too 
elevated47,48. A second example is represented by DICER that is an 
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haploinsufficient tumour suppressor gene. Uncontrolled miR over-expression may 
repress DICER function and cause a tumour-prone environment49. All these 
issues are not associated to anti-miR technology where a single miR is silenced 
and not over-expressed. In conclusion, even tough pre-clinical studies like this 
report represent a good proof of principle they will need clinical trial evaluation to 
address several question associated to efficacy, toxicity and off target effects.  
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Materials and Methods 
 
MicroRNA and mRNA expression analysis 
MicroRNA expression profiling and mRNA expression of cancer associated genes 
were analyzed using Nanostring nCounter Technology (Seattle WA0 using the 
nCounter Mouse miRNA Expression Assay Kit and the nCounter Human Cancer 
Reference Kit respectively. NanoString nCounter gene expression system 
quantitates abundances of miRNAs and mRNA. Technical normalization was 
performed using the synthetic positive controls to adjust the counts for each 
miRNA/mRNA target in that assay. Then biological normalization is performed to 
correct for differences in sample abundances. Each sample is normalized to the 
geometric mean of the top 50 most highly expressed miRNAs/mRNA. Students t-
test is used on normalized counts to calculate statistical significances of pair-wise 
comparisons . All of the calculations are performed in R statistical computing and 
graphics environment (http://www.r-project.org). 
  
Cell Cultures and Transfections 
SW620, SW480, HCT-116, DLD-1 and RKO colorectal cancer (CRC) cells 
(American Type Culture Collection ATCC Manassas, VA) were cultured in RPMI 
1640 (Gibco, Carlsbad, CA). PI3KCA mutant and WT HCT-116 and DLD-1 cells 
(kind gift Prof Bert Vogelstein Johns Hopkins University Baltimore MD USA)) were 
grown in McCoy’s 5A modified medium  (Gibco, Carlsbad, CA). All cells were 
supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO) plus 
antibiotics. For serum starvation, cells were grown to 70%–80% confluency, 
washed once with PBS, and incubated for 19 hr in McCoy’s 5A modified medium 
containing 0.5% FCS.  Normal epithelial colon cell lines NCM356 and NCM4060 
(InCell San Antonio, TX) were cultured in M3:10TM medium. Mouse Embryo 
Fibroblasts were provided by Prof. Peter K Vogt (Scripps Research Institute La 
Jolla CA USA) and cultured in 10% DMEM plus antibiotics. Cells were examined  
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for Mycoplasma contamination periodically and were always found negative.  Cell 
transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) 
following manufacturer’s protocol. For over-expression studies specific miRNA or 
control precursor oligonucleotides were purchased from Ambion (Austin, TX) and 
used at 20 nM. On target-plus siRNA pools and relative controls were purchased 
from Thermo Fisher Scientific (Lafayette, CO).  For silencing experiments 
miRCURY LNA™ anti-miR-135b or control miRCURY knockdown probes (Exiqon, 
Vedbaek, Denmark) were used at 25 nM.  EGFP-APC and empty control vectors 
were a gift from Prof Joanna Groden (OSU OH USA). The PI3K inhibitor 
LY294002 was purchased at Cell Signaling (Beverly MA) and used as described 
previously at 10 μM. Dasatinb (Selleck Chemicals Houston, TX) was used as 
previously described at 100nmol/L. AS703026 a MEK1-2 inhibitor (Selleck 
Chemicals Houston, TX) was used as previously described at 10 μmol/L 
 
Luciferase Assay  
The predicted miRNA binding sites in the 3’-UTR of FIH, TGFβR2 and APC were 
cloned downstream of the firefly luciferase gene as follows. Complimentary DNA 
(cDNA) from NCM4060 cells was amplified by PCR using specific primers 
(primers sequences available upon request). The product was then digested with 
SpeI and SacII (New England Biolabs Ipswich, MA) and inserted into the pGL3 
control vector (Promega, Madison, WI) previously modified to harbor the SpeI and 
SacII sites immediately downstream of the stop codon of the firefly luciferase 
gene. The DAPK1-3’UTR plasmid was purchased at SwitchGear Genomics 
(Menlo Park, CA) and transfected as previously described50. Mutant plasmids 
harboring a deletion in the miR-135b seed region were prepared, for each target 
gene, using QuikChange site-directed mutagenesis kit (Stratagene, San Diego, 
CA). NCM 4060 cells were co-transfected in 12-well plates with 1 µg of pGL3 
firefly luciferase reporter control vector, 0.1 µg of the phRL-SV40 control vector 
(Promega, Madison, WI), and 20 nM pre-miR-135b or  control precursors. Firefly 
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and Renilla luciferase activities were measured consecutively by using the Dual 
Luciferase Assay (Promega) 24 hours after transfection.  
 
Western Blotting  
For immunoblotting analysis cells were lysed with ice-cold Cell Lysis Buffer plus 
protease inhibitor (Cell Signaling Technology Inc. Danvers, MA). Equivalent 
amounts of protein were resolved and mixed with 4X SDS-PAGE sample buffer, 
electrophoresed in a 4%–20% and 7.5% linear gradient Tris-HCL Criterion Precast 
Gels (Bio-Rad), and transferred to nitrocellulose or PVDF membranes (Bio-Rad). 
The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline, pH 
7.4, containing 0.05% Tween 20, and were incubated with primary and secondary 
antibodies according to the manufacturer’s instructions. The following Antibodies 
were used: Phospho-Akt Pathway Sampler Kit  (Cell Signaling cat n 9916); Anti-
DAP Kinase 1 rabbit (Sigma cat n D1319); Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (Cell Signaling cat n 9101S); p44/42 MAPK (Erk1/2) (Cell 
Signaling cat n 9102); FIH (Cell Signaling cat n D19B3); β-Catenin (Cell Signaling 
cat n #9562); p21 Waf1/Cip1 (12D1) Rabbit (Cell Signaling cat n #2947); TGF-β 
Receptor II (K105) (Cell Signaling cat n #3713) GAPDH (St Cruz CA)  
           
      
Real time PCR for mature miRNAs and genes  
Total RNA was isolated using Trizol (Invitrogen). Mature miRNAs expression was  
assessed by single-tube TaqMan MicroRNA Assay, while the expression of 
mRNAs of interest was evaluated by the Gene Expression analysis using Syber-
Green or Taq-man Probes.  For Syber-Green, RNA was treated with RNase-free 
DNase I (Qiagen). One microgram of RNAwas reverse-transcribed to cDNA, and 
quantitative real-time PCR was performed with specific primers for IL8, VEGF, 
DAPK1, FIH, APC and TGFβR2 (list of primers available upon request). TaqMan 
Probes were as follow: TGFBR2 (Hs00234253_m1), HIF1AN (Hs00215495_m1), 
DAPK1 (Hs00234489_m1). miRNA expression was normalized to that of RNU44 
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and RNU48.  Gene expression was normalized to GAPDH. All retrotranscriptase 
(RT) reactions, including no-template controls and RT minus controls, were run in 
a GeneAmp PCR 9700 Thermocycler (Applied Biosystems). Each sample was 
tested in triplicate. 
 
Cell Death analysis 
Propidium iodide (PI) staining: cells were detached with trypsin, washed with cold 
phosphate-buffered saline (PBS)–5% FCS and then fixed in 70% ethanol for 24 h. 
After washing with PBS, cells were incubated with 1 μg/ml PI for 3 h at 25°C 
before FACS analysis by Coulter Epics XL flow cytometer (Beckman Coulter, 
Fullerton, CA). Cells were considered apoptotic when their DNA content was <2N.  
For detection of caspase-3/7 activity, cells were plated in 10cm dishes transfected 
with pre-miR-135b, siRNA to p21 or TGFβR2. The day after transfection cells 
were harvested and re-plated in 96-well plates in quadruplicate, treated with 10 
μM TGF and analyzed using a Caspase-Glo 3/7 Assay kit (Promega) according to 
the manufacturer's instructions. 
Focus formation assay in soft agar 
HCT116 transfected with pre-miR-135b, LNA anti-miR-135b or relative contols 
were plated in triplicate at 5000 cells/ml in top plugs consisting of McCoy’s 5A 
modified medium containing various FCS concentrations and 0.4% SeaPlaque 
agarose (FMC Bioproducts, Rockland, Maine). After two weeks, the colonies were 
photographed and counted. When all colony sizes were considered, the total 
number of colonies formed by WT and mutant clones was essentially the same. 
However, when colonies above the threshold of 2 mm were counted, differences 
between the number of WT and mutant clones were observed. 
Cell viability assays.Cell viability was examined with 3-(4,5-dimethylthiazol-2-yl)-
2,5-dipheniltetrazolium bromide (MTS)-Cell Titer 96 Aqueous One Solution Cell 
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Proliferation Assay (Promega) according to the manufacturer's protocol. 
Metabolically active cells were detected by adding 20 μl of MTS to each well. After 
1 h of incubation, the plates were analyzed in a Multilabel Counter (Bio-Rad 
Laboratories). 
Tube Formation Assay NCM 4060 cells were transfected with pre-miR-135b or 
pre-miR-control under starvation. 16 hours after transfection media from both 
experiments was collected and used to culture HUVEC Matrigel (BD PharMingen; 
12.9 mg/mL)–coated LabTek (55,000 cells per chamber). Results are expressed 
as number of tube-like structures per field (magnification, ×200).  
Tissue Collection 
Fresh frozen tissues from tumor and normal adjacent tissue from 62 cases of CRC 
were collected at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei 
Tumori, Meldola, Italy after approval of the ethical committee. Cell lysates for 
protein and RNA extraction were extracted previousy described. Nine cases of 
Inflammatory Bowel Disease (IBD) associated CRC and matched normal tissues 
were collected at the OSU Pathology Archive. Six cases of IBD associated CRC 
were collected at the Department of Pathology at the University of Ferrara Italy. In 
four of these cases high grade dysplasia was also availbale. 
 
Animals and Tumor Induction 
RNAs from Apc+/Δ716 Cdx2+/– (matched cancer and normal), Azoximehtane 
(AOM)/Dextran Sulphate Sodium (DSS) (matched cancer and normal), Wild Type 
(untreated normal epithelium) and short term DSS treated mice (inflamed 
epithelium)  for the initial microRNA expression screening were provided by Prof 
Michael Karin (UCSD USA). RNA from long term (78 days) DSS treated mice 
(inflamed epithelium) was collected at OSU. All mice were C75BL/6 strain mice. 
For in vivo silencing experiments C57BL/6 mice were obtained from The Jackson 
Laboratory. All mice were maintained in filter-topped cages on autoclaved food 
and water at OSU according to NIH guidelines, and all experiments were 
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performed in accordance with OSU and NIH guidelines and regulations. CAC was 
induced as described previously.  Briefly, on day 1, mice were injected intra-
peritoneally (i.p.) with 12.5 mg/kg azoxymethane (AOM; National Cancer Institute) 
and maintained on regular diet and water for 7 days. After 7 days, mice received 
water with 2.5% dextran sulfate sodium (DSS; MP Biomedicals, molecular weight 
35,000–50,000 kDa) for 5 days. After this, mice were maintained on regular water 
for 14 days and subjected to two more DSS treatment cycles.  
Mice were treated as follows: 
AOM + DSS + Scrambled-AMO (Scrambled-AMO group) (n=8) C57BL/6  8 weeks 
old mice were treated with AOM i.p. at day 0 and received 2.5% DSS water 
accordingly to the above mentioned schedule. Anti-miR-control was given twice a 
week for the entire treatment (22 injections over a 11 weeks period) at 75mg/kg. 
AOM + DSS + miR-135b-AMO (135b-AMO treatment group) (n=8) C57BL/6  8 
weeks old mice were treated with AOM i.p. at day 0 and received 2.5% DSS water 
accordingly to the above mentioned schedule. Anti-miR-135b was given twice a 
week for the entire treatment (22 injections over a 11 weeks period) at 75mg/kg. 
AOM + DSS (Mock Group) (n=8) C57BL/6  8 weeks old mice were treated with 
AOM i.p. at day 0 and will receive 3% DSS water accordingly to the above 
mentioned schedule. No anti-miRs were administered. 
Macroscopic tumors were counted and measured with a caliper. Tumors and 
matched normal adjacent tissues from the distal colon were taken as a tissue 
sample and snap frozen in liquid nitrogen, maintained in Trizol or fixed in 10% 
neutral buffered formalin for 24 hr and transferred to 70% ethanol for subsequent 
paraffin embedding and histological analysis. The clinical course of disease was 
followed daily by measurement of body weight and monitoring for signs of rectal 
bleeding or diarrhoea. 
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Histological Analysis 
Colons were examined using 4 μm thick, 200 μm step serial sections stained with 
hematoxylin and eosin. For TUNEL assay, an In Situ Cell Death Kit (Roche) was 
used according to the manufacturer's recommendations. MicroRNA detection was 
performed on colon cancer tissues from mice intestines or human colon cancer 
sections by in situ hybridization (ISH) as previously described51.  The negative 
controls included omission of the probe and the use of a scrambled LNA probe. 
Immunohistochemistry for Ki-67 was performed as previously described at the 
OSU core pathology facility.  
 
Statistical Analysis 
Expression graphs and Wilcoxon matched-pairs tests were used to analyze 
differences in microRNA expression between tumors and paired nontumorous 
tissue for all quantitative RT-PCR data using Graphpad Prism 5.0 (Graphpad 
Software Inc, San Diego, California). Associations with prognosis in the sporadic 
CRC cohort were considered statistically significant only if the P value were less 
than .01 to adjust for multiple comparisons testing (5 tests using a Bonferroni 
correction). KaplanMeier analysis was performed with WINSTAT 2001 (R Fitch 
Software, Bad Krozingen, Germany). Multivariate Cox regression analysis was 
performed using StataCorp 9.2. For these models, we dichotomized age as 50 
years or older vs younger than 50 years because the recommended screening 
age for colon cancer is at age 50 years; TNM staging was dichotomized based on 
metastasic vs nonmetastasic disease. Univariate Cox regression was performed 
on each clinical covariate to examine influence of each on patient survival. Final 
multivariate models were based on stepwise addition and removal of clinical 
covariates found to be associated with poor survival in univariate models (P < 
.10). A Wald statistic of P < .05 was used as the criterion for inclusion in final 
multivariate models. All stepwise addition models gave the same final models as 
stepwise removal models. All P values reported are 2-sided. All univariate and 
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multivariate Cox regression models were tested for proportional hazards 
assumptions based on Schoenfeld residuals, and no model violated these 
assumptions. Results of statistical analyses are expressed as mean ± SD unless 
indicated otherwise. Comparisons between groups were performed using the two-
tailed Student's t test. A P value <0.05 was considered significant. Graphpad 
Prism version 5.0 was used for Pearson correlations. 
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Figures 
 
 
 
 
 
 
 
 
 
Figure 1. A. Genome-wide expression miRNA profiling was performed in colon tissue from 
APC vs WT mice. On the right panel the ratio of expression of selected miRNAs (p<0.001) in 
cancer relative to normal tissue is plotted against the p-value. B. Same analysis as above in 
mice treated with AOM-DSS to study inflammation-induced CRC.  
 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A. miR-135b expression was assessed by real time PCR in mouse tissues. The 
expression of miR-135b was normalized to that of RNU135. Bars represent mean and SEM 
of 3 samples. Significant comparisons are annotated. B. Paraffin-embedded, formalin-fixed 
colon tissues were incubated with LNA-anti-miR-135b.  
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Figure 3. hsa-miR-135b expression was assessed by real time PCR in human tissues. The 
expression of miR-135b was normalized to that of RNU48. A. Expression of hsa-miR-135b in 
sporadic CRCs. Bars represent the mean and SD. B. hsa-miR-135b expression in sporadic 
CRCs by stages. C. hsa-miR-135b expression in an American cohort of IBD-associated 
CRCs. D. hsa-miR-135b expression in an Italian cohort of IBD-associated CRCs. E. Paraffin-
embedded, formalin-fixed sporadic CRC tissue was incubated with LNA-anti-miR-135b.  
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Figure 4. miR-135b expression was assessed by real time PCR in human tissues from 
sporadic CRCs. The expression of miR-135b was normalized to that of RNU48 and 
expressed in log2 scale. The ratio between the expression of mi<r-135b in cancer and 
normal was divided in: Low miR-135b 2, while high mR-135b >2. Kaplan Meyer analysis 
was performed in all stages (A), stages I to III (B), stages II and III (C), and stage II (D). 
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Figure 5. Relapse and Overall Survival was analyzed by Kaplan Meyer analysis in sporadic 
CRCs according to stage and nodal status. 
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Figure 6. hsa-miR-135b expression was assessed by real time PCR in human CRC cell 
lines. The expression of miR-135b was normalized to that of RNU48, while that of other 
genes to GAPDH. Bars represent the mean and SD of 3 experiments. A&B. Expression of 
hsa-miR-135b after transfection with siRNA to APC in NCM 4060  and NCM356 cells. C&D. 
hsa-miR-135b expression after transfection with a vector over-expressing CTNNB1 (-
catenin). E. hsa-miR-135b expression after treatment with NaCl and LiCL. F&G&H. hsa-
miR-135b expression after transfection with selected siRNA as indicated. Statistically 
significant comparisons are reported. 
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Figure 7. mmu-miR-135b expression was assessed by real time PCR in mouse embryo 
fibroblasts with genetic aberrations. The expression of miR-135b was normalized to that of 
SNU234.  
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Figure 8. A&B. hsa-miR-135b expression was assessed by real time PCR in human CRC 
cell lines with or without mutation of the PI3K after exposure to 10% or 0.5% of Fetal Bovine 
Serum (FBS). Bars represent mean and SD of 3 experiments. 
 
 
 
 
 
 
53 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. A. hsa-miR-135b expression was assessed by real time PCR in human CRC cell 
lines with or without mutation of the PI3K after exposure to the PI3K inhibitor (LY-294002). 
Bars represent mean and SD of 3 experiments. B. Inhibition of pAKT by LY-294002. C. hsa-
miR-135b expression was assessed by real time PCR in human CRC cell lines with or 
without mutation of the PI3K after transfection with selected siRNAs. Bars represent mean 
and SD of 3 experiments. D. Inhibition of FOXO1 and 3a protein expression by siRNAs.  
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Figure 10. A. hsa-miR-135b expression was assessed by real time PCR in human CRC cell 
lines after treatment with Dasatinib. Bars represent the mean and SD of 3 experiments. B. 
Inhibition of pSRC by Dasatinib. C. mmu-miR-135b expression was assessed by real time 
PCR in mouse embryo fibroblasts after treatment with Dasatinib. Bars represent the mean 
and SD of 3 experiments. D. mmu-miR-135b expression was assessed by real time PCR in 
mouse embryo fibroblasts after treatment with  PI3K inhbitor and MEK1/2 inhibitor. Bars 
represent the mean and SD of 3 experiments. E. Inhibition of pAKT and pERK respectively 
in MEF-SRC. 
 
 
55 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. A. Schematic model of the genomic site of hsa-miR-135b. B. LEMD1 mRNA 
expression was assessed by real tIme PCR and normalized to GAPDH. 
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Figure 12. Analysis of apoptosis was performed by flow cytometry. Proportion of propidium 
iodide positive cells in the different groups of treatment is shown on the left side and 
quantitated in the right side. 
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Figure 13. hsa-miR-135b expression was evaluated after transfection with selected probes 
as indicated.  
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Figure 14. A. Human CRC cells were transfected for 48 hours with selected probes as 
indicated and then plated. After selected time points cell viability was measured by MTT 
assay. Mean values of 3 independent experiments with SD are represented. B&C. Human 
CRC cells were transfected for 48 hours with selected probes as indicated and then plated in 
soft agar. Colonies greater than 2 mm in size were counted and quantitated. Representative 
images are shown.  
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Figure 15. A. Human CRC cell lines were treated with a probe anti-miR-135b (miR-135b-
AMO) or a scrambled probe (scrambled-AMO) and miR-135b expression assessed by real 
time PCR. B. expression of miR-21, miR-155, miR-221 and let7-d was evaluated to test 
135b-AMO off-target effects. C. Mice were treated with miR-135b-AMO or scrambled-AMO 
and colon tissue collected. ISH was assessed with an anti-anti-miR-135b. Colon tissues 
were positive to indicate that miR-135b-AMO could reach the colon tissue in vivo.  
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Figure 16. Schematic representation of the mice treatment. AOM was given once, followed 
by periodic administration of DSS (in water for 7 days ever). miR-135b-AMO or scrambled-
AMO was given twice a week from the beginning of treatment for 100 days. 
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Figure 17. Mice (n=8) were treated with miR-135b-AMO or scrambled-AMO and colon 
collected and analyzed for presence of tumors. miR-135b-AMO reduced the number and the 
size of colon tumors. 
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Figure 18. Mice (n=8) were treated with miR-135b-AMO or scrambled-AMO or no treatment 
(control) and colon collected and analyzed for presence of tumors. Macroscopic (A) and 
microscopic (B) representative images are shown. 
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Figure 19. miR-135b expression was assessed by real time PCR (A) and ISH (B) in cancer 
tissues from mice treated with miR-135b-AMO or scrambled-AMO or control.  
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Figure 20. A. Cancer tissues from mice treated with miR-135b-AMO or scrambled-AMO 
were analyzed by IHC for Ki-67 expression. miR-135b-AMO reduced Ki67 index. B. Cancer 
tissues from mice treated with miR-135b-AMO or scrambled-AMO were analyzed by 
immunofluorescence for TUNEL and DAPI expression. miR-135b-AMO increased apoptotic 
(TUNEL positive) cells. 
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Figure 21. Lungs, livers, kidneys and spleens from miR-135b-AMO and scrambled-AMO 
treated mice were compared. No differences were found. 
 
 
 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Expression of hsa-miR-135b in a panel of human CRC cell lines. Bars represent 
mean and SD of 3 samples. 
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Figure 23. A. Gene expression in 4060NCM cell transfected with pre-miR-135b or 
scrambled probe. B&C&D&F RT-PCR- in NCM4060 cells transfected with pre-miR-135b. 
Results represent mean and SD of three different experiments. 
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Figure 24. A RT-PCR for miR-135b in NCM4060 transfected cells. RT-PCR for B TGFβR2 
C DAPK1 D APC E FIH expression in NCM4060 cells over-expressing miR-135b compared 
to scrambled transfected cells. Results represent mean and SD of three different 
experiments. 
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Figure 25. Luciferase experiments for TGFβR2, DAPK1, APC and FIH in NCM4060 
transfected with target-gene-Luc-WT or target-gene-Luc-mutant, pre-miR-135b or scrambled 
miR plus renilla as control. Results represent mean and SD of three different experiments. 
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Figure 26. Western blotting analysis in cells transfected with pre-miR-135b or  scrambled 
miR or selected siRNA. 
 
 
